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Abstract
Cancer of the uterine cervix is caused by a subset of oncogenic human Papillomavirus (HPV)-types with mucosal tropism. Besides the known effects of the viral 
oncoproteins on cellular functions there is evidence suggesting that cervical carcinogenesis involves epigenetic changes in the host DNA. In this study, we have 
examined the global promoter methylation profile associated with progression to cervical cancer at wide genome scale. The methylation pattern of nearly 14,000 genes 
was analyzed in cervical swabs at different stages of cervical carcinogenesis: low-grade cervical intraepithelial neoplasia (CIN I and II), high-grade CIN (CIN III) 
and invasive cancer, as well as healthy individuals. Unsupervised analysis (Hierarchical Clustering) identified two groups: A) healthy, CIN I and CIN II; and B) CIN 
III/cancer. Supervised T-Test analysis showed 1069 promoter regions hypermethylated and 85 hypomethylated in CIN III/cancer compared to CIN I/CIN II and 
healthy samples (p<0.0001). Overall, the differentially methylated genes act in transcription, cell cycle, apoptosis and cell adhesion pathways.  Of the hypermethylated 
genes, 132 (12.3%) were down-regulated in a matched cervical cancer group. In turn, only 4 (4.7%) of the hypomethylated genes were overexpressed in that group. 
These data suggest that, although significant changes in methylation of a large number of cellular promoters take place during progression to cervical cancer, 
correlation between methylation and altered gene expression occurs only in a reduced number of genes. Nevertheless, these genes are relevant to cell transformation. 
Our results support the prognostic value of methylation profiling of a larger number of genes than previously thought.
Introduction
Cervical cancer (CC) of the uterus is the third most frequent cancer 
in women worldwide with over half a million new cases estimated in 
the year 2012 [1]. Over 85% of the cases occur in developing countries. 
In Colombia, the estimated incidence of CC is 21.5 cases per 100.000 
inhabitants [1]. The cervical carcinogenesis begins with non-invasive 
dysplastic lesions, which progress to cervical intraepithelial neoplasia 
(CIN) grades I to III and, in some cases, the lesions persist and progress 
to invasive carcinoma [2]. A few high-risk human papillomaviruses 
(HPVs), most notably HPV16 and HPV18, are in the etiology of the 
majority of CCs, as well as other anogenital tumors and an increasing 
number of head and neck cancers [3]. Two proteins encoded by these 
viruses, E6 and E7 have transforming capabilities by inactivating RB1 
and promoting degradation of TP53 thereby interfering with signaling 
pathways and cell cycle control mechanisms [4]. However, the natural 
history of the disease shows that only a minority of women infected 
with high-risk HPVs cannot clear infection and develop CC [5]. The 
molecular mechanisms that determine clearance or persistence of the 
HPV infection are mainly unknown. Thus, to date there are no reliable 
molecular markers that may help predicting whether low-grade lesions 
will progress to cancer or rather regress and be cleared. 
Cancer cells develop their malignant phenotype through a series of 
concurrent genetic and epigenetic changes that cooperatively influence 
gene transcription and contribute to overall malignant transformation 
[6]. The epigenetic machinery plays an important role in the control 
of the transcriptional activity through DNA modifications, most 
importantly CpG cytosine-5 methylation [6]. The human genome 
can be envisioned as immense regions of DNA sequence containing 
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“Novelty and Impact”: Genome wide methylation analysis of cervical swabs of a cohort of cervical intraepithelial neoplasia CIN I-III and cervical cancer patients 
revealed a large number of genes with hypermethylated promoter, and a markedly lower number hypomethylated, in CIN III and cervical cancer. Our results support 
the prognostic value of methylation profiling of a larger number of genes than previously thought. These can be readily identified in swabs rather than biopsies, which 
facilitates their clinical use as prognostic markers.
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DNA methylation profiles of low and high-grade CIN and cervical 
cancer as well as normal cervix exfoliates. Supervised T-Test analysis 
of the methylation patterns in CIN and cancer exfoliates identified an 
overwhelming number of hypermethylated gene promoters in contrast 
to a reduced number of hypomethylated genes. Further analyses of data 
on expression of those genes revealed discrepancy in the correlation 
between methylation status and expression levels. 
Methods
Patients and samples
This study is based on a descriptive, cross-sectional and observational 
analysis. All tissue samples were obtained after signed informed 
consent of all participating patients and healthy donors with approval 
of the institutional review board. The number of patients included in 
this study was calculated according to biometric parameters. Cervical 
specimens were collected over a period of 3 months in a hospital 
(Dinamica-IPS) of the city of Bogotá. Trained medical personnel took 
the cervical swabs. The cohort of patients included 3 women with no 
signs of cervical pathology, and 17 patients with confirmed cervical 
histopathologic diagnosis, namely: 4 with CIN I, 4 with CIN II, 3 with 
CIN III, 3 with in situ squamous cell carcinoma (SCC) and 3 with 
invasive SCC. None of these patients had been subjected to treatment 
before the cervical swabs were collected. 
The cervical swabs for this study were deposited in PBS containing 
0.05% thimerosal. DNA was isolated from these samples by phenol-
chloroform extraction and subsequently used for bisulfite conversion 
and methylation analyses by BeadChip microarray (see below) and 
for multiplex HPV genotyping (see below). The quality control of 
the samples was performed by spectrophotometric measuring at 
OD260/230 and OD260/280 within a range of 1.0-3.0 and a concentration of 
approximate 1500ng/μL using a Nanodrop1000®. 
Bisulfite conversion of genomic DNA
The bisulfite conversion of genomic DNA was performed using 
the EZ Methylation Kit (Zymo Research, D5002), following the 
manufacturer's instructions. Briefly, DNA concentration was measured 
by fluorescence using Quant-iT™ PicoGreen®, and 1μg of DNA was 
mixed with a buffer solution and incubated at 37°C for 15 minutes, 
subsequently mixed with the conversion reagent and incubated in 
a thermocycler for 16 cycles at 95°C for 30 seconds and 50°C for 60 
minutes. Finally, the samples were converted, desulphonated and 
purified according to the manufacturer's recommendations.
Human Infinium Methylation27 Illumina BeadChip
The converted genomic DNA was analyzed by Illumina Infinium 
BeadChip Methylation27 Human Kit at the Made-Radiumhospitalet 
Rikshospitalet Medical Center / University of Oslo Microarray Core 
Facility (Norwegian Microarray Consortium). The BeadChip assay 
provides quantitative measurements of DNA methylation for 27578 
CpG dinucleotides covering the promoter region of 14,495 human 
genes. Chip data processing and analysis was performed using Illumina 
reagents and following the manufacturer's instructions. The procedure 
began with DNA denaturation converted with 0.014N sodium 
hydroxide, neutralized and amplified for 20-24 hours at 37°C. The 
samples were hybridized to the BeadChip at 48°C for 16-20 hours. After 
incubation, the beadchips were washed with buffer and placed in the 
Fluidics Station finally the image was captured on the Illumina iScan 
scanner. The data were obtained using the BeadStudio v3.0 software. 
The heatmap was obtained with the Multiexperiment Viewer software.
methylated CpG dinucleotides distributed randomly (CpG oceans), 
short regions of higher density, unmethylated CpG dinucleotides (CpG 
islands), and transition regions (CpG shores) with conserved tissue-
specific methylation [7]. CpG islands are present in the promoter 
regions of nearly half of the actively transcribed human genes. They 
are unmethylated in normal cells, but often hypermethylated in 
cancer cells, and this is an epigenetic change typically associated with 
transcriptional repression. From a functional point of view, the presence 
of methyl groups on cytosines can result in the local alteration of the 
structure of chromatin by the union of binding proteins to methyl-
cytosine, chromatin remodeling proteins and histone deacetylases, 
all of which hinder recognition of promoter sequences by the cellular 
transcription machinery. Besides, it is conceivable that methylation 
patterns characteristic of cancer cells could be identified in early stages 
of carcinogenesis, and hence methylation biomarkers may help in early 
detection and/or prognostic assessment of CC.
The use of high-performance platforms for evaluating profiles of 
methylation allows detection of large numbers of methylated genes 
that are possibly associated with the tumorigenesis process.  Currently 
there are several methodologies to determine the methylation profile 
of genomic DNA samples. In a general way, these methods include 
[8]: (i) DNA digestion with methylation-sensitive restriction enzymes, 
combined bisulfite restriction analysis (COBRA), methylation-
specific PCR (MSP), which require at least 1-10 ug per sample; (ii) 
methodologies based on proteins or antibodies that can bind to the 
methyl group, which have the disadvantage of allowing the processing 
of only limited numbers of samples in parallel; and (iii) genome-wide 
DNA methylation profiling, such as the Illumina Infinium platform, 
that generally require from 500ng to 1ug of DNA and allows the 
processing of larger numbers of samples simultaneously.
In cervical cancer cells carrying one or more oncogenic HPV types 
de novo CpG methylation occurs in both viral and host DNA. It has 
been shown that the DNA of HPV16 and HPV18 in pre-immortal 
keratinocytes is almost completely unmethylated while it is heavily 
methylated in their immortalized derivative cells [9]. In addition, these 
studies showed increasing hypermethylation of the CpG islands in the 
HPV DNA during progression from dysplasia to invasive cancer. On the 
other hand, analyses of the methylation status of the host genome have 
shown that the promoter region of over 50 genes is hypermethylated in 
cervical cancers as well as their exfoliated cells [10]. At least 15 of these 
genes were studied also in CIN2 and CIN3 and showed intermediate 
methylation levels. Only a few of these genes were analyzed in several 
independent studies [10], most of which used MSP, quantitative MSP 
(qMSP), bisulfite sequencing or methylation-sensitive restriction 
analysis. The most significant genes found hypermethylated in cervical 
cancer in previous studies were CDH1, MAL, TFP12, DAPK1, RARB 
and TWIST1[11]. A panel including the last three genes was claimed 
to show high sensitivity and specificity for early detection of cervical 
cancer. However, a meta-analysis of 51 studies on methylation in 
cervical cancer showed that there is a high variability in the rate of 
methylation of a given gene among different studies [11].
Therefore, there is still a need for extensive, genome-wide 
methylation studies that may help elucidate the role of epigenetic 
modifications in progression from dysplastic lesions to cervical cancer 
and find methylation biomarkers with prognostic value. The use of 
microarrays allows simultaneous assessment of the methylation status 
of virtually any gene in cervical cancer and CIN in comparison with 
normal tissue. In the present study we have used the Illumina Human-
Methylation27 Infinium BeadChip to compare the genome-wide 
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Multiplex HPV Genotyping (MPG) 
Multiplex BSGP5+/GP6+ PCR-MPG was carried out with primers 
reported previously [12] essentially as described [13]. The assay 
used nine sense primers BSGP5+ at 200 nM and 3 antisense primers 
5'-biotinylated-BSGP6+ at 400 nM to amplify a ~150 bp fragment of the 
viral L1 ORF, as well as two additional primers (MS3/MS10) at 300 nM 
to amplify the ß-globin gene, which was used as DNA integrity control. 
The multiplex Luminex hybridization assay enabled the detection of 27 
mucosal HPV-genotypes: i) high risk (HR)-HPV types: 16, 18, 31, 33, 
35, 39, 45, 51, 52, 56, 58, 59, 66, 68; ii) possibly HR-HPV types: 26, 53, 
67, 70, 73, 82; iii) low risk (LR)-HPV types: 6, 11, 30, 43, 44 and 69. In 
addition, the β-globin product was amplified in each sample.
Oligonucleotide probes with an amino group at the 5' end for 
each of the 27 HPV types were coupled to carboxylated beads using 
the carbodiimide procedure as described previously [14]. For each 
combination of probes and beads we used 2.5 million carboxylated beads 
in 25 µL of 0.1 M2-(N-morpholino) ethanesulfonic acid (MES), pH 
4.5, with 200 µg of N-(3-dimethylaminopropyl)-N-ethylcarbodiimide 
(EDC) and 400 pmol of probe, the mixture was incubated in the dark 
under stirring for 30 minutes, the addition of EDC and incubation was 
repeated once, then the beads were washed with 0.5 ml of 0.2 g/L of 
Tween 20 and once with 0.5 ml of 1.0 g/L SDS. Finally, they were stored 
at 4°C in TE solution. Hybridization was performed in 96 well plates 
with 10 µL of PCR product in 33 µL of hybridization solution (0.15 M 
of tetramethylammonium chloride (TMAC), 75 mM Tris-HCl, 6 mM 
EDTA, 1.5 g/L Sarkosyl, pH 8.0) to which 2000 bead-coupled probes 
were added. This mixture was incubated at 95°C for 10 minutes and 
immediately placed on ice for 2 minutes, then it was placed at 41°C for 
30 minutes under stirring, then the samples were transferred to a wash 
plate with filter bottom (Millipore, Bedford, MA) pre-equilibrated with 
blocking solution (PBS with 0.2 g/L Tween-20 and 2.0 M TMAC), and 
washed with blocking solution to eliminate non-hybridized DNA in 
a vacuum wash station (Millipore). Subsequently, biotinylated PCR 
products were stained with streptavidin-R-phycoerythrin conjugate 
(Molecular Probes) diluted 1:1600 in 2.0 M TMAC, 75 mM Tris-HCl, 
6 mM EDTA, 1.5 g/L Sarkosyl, 1.0 g/L casein, pH 8.0 and incubated 20 
minutes at room temperature with shaking. After washing three times 
with blocking solution, the beads were analyzed in a Luminex 100 
reader (Luminex Corp.), which uses two lasers, one that recognizes the 
bead set by the internal bead color and another to quantify the reporter 
fluorescence on the bead. The results were expressed in median 
fluorescence intensities (MFI) of ≥100 beads per sample [12,14]. 
HPV16 and HPV18 transcript copy number
We analyzed the expression of the early gene E7 of HPV16 and 
HPV18. To this end, we isolated total RNA from biopsy material 
included in paraffin with the kit RNeasy FFPE (Qiagen®). After DNase I 
treatment and reverse transcription with the kit “High Capacity RNA-
to-cDNA” (Applied Biosystem®) and analyzed them by quantitative 
real time PCR (qRT-PCR) using specific primers for E7 and E6/E7 
transcripts (Supplementary Table 1). The estimation of the transcript 
copy number was made by absolute quantification using known 
amounts of HPV-16 and HPV-18 DNA to generate a standard curve.    
Statistical and bioinformatic analyses
Statistical analyses and heat map visualization were performed 
with the MultiExperiment Viewer software (MeV 4.6) [15], with 
an unsupervised cluster analysis with Euclidian distance to create a 
heatmap. This analysis showed that there was a turning point in gene 
methylation between the group of negative, CIN I and CIN II samples, 
and the group of CIN III, in situ carcinoma and invasive cancer. The 
Benjamini and Hochberg method [16] was used to adjust the p-values 
for multiple testing. The selection of differentially methylated genes was 
performed with T-test p = 0.0001. For automated functional annotation 
and gene enrichment analysis, we used the Database for Annotation, 
Visualization and Integrated Discovery (http://david.niaid.nih.gov/
david) [17]. The DAVID resource calculates over-representation of 
specific biological themes/pathways with respect to the total number of 
genes assayed and annotated. The REVIGO resource was employed to 
summarize and visualize the enriched GO terms in an interactive graph 
based on the p-values obtained by DAVID [18].
The microarray analysis of gene expression used in this study was 
the Affymetrix HG-U133A platform and Gene Expression Omnibus 
(GEO) (URL: www.ncbi.nlm.nih.gov/geo) accession number GSE7803 
[19]. The selection of differentially expressed genes was performed 
with an unsupervised cluster analysis with Euclidian distance and p = 
0.0001. Finally, a correlation of hypermethylation and down-regulation 
of expression was performed using contingency tables.
The dataset generated in this study is available and can be retrieved 
from the Gene Expression Omnibus (GEO; www.ncbi.nlm.nih.gov/
geo/) accession number GSE41384.
Results
Selection of patients, HPV detection and genotyping
Previous studies have identified cancer-specific DNA methylated 
regions and it has been suggested that increased methylation variability 
involves loss of epigenetic stability of well-defined genomic domains 
[20]. In addition, algorithms are being developed that could help 
predict progression of precursor lesions to invasive cancer [21]. Studies 
on differential DNA methylation are expected to identify sets of genes 
that, according to their methylation status, could determine the altered 
expression of their encoded proteins in cervical cancer and its precursor 
lesions compared with normal cervical tissue. In addition, their changes 
in methylation during cancer progression could be of prognostic value. 
The present study was designed to analyze methylation profiles in DNA 
purified from cervical exfoliates taken from CIN and cervical cancer 
patients, and healthy donors before the histopathologic diagnosis was 
made. Such samples offer the advantage of being easily accessible and 
do not require invasive techniques for their collection. In contrast, 
methods based on the analysis of DNA obtained directly from cervical 
dysplastic tissue require taking biopsy samples, which can have local 
side effects such as hemorrhage and, eventually, could contribute to 
spread the initial lesion to underlying tissues.
The DNA samples investigated in this study were purified from 
cervical swabs of 20 donors who were subsequently diagnosed of 
CIN I (n=3), CIN II (n=4), CIN III, carcinoma in situ (n=6) and 
invasive cervical cancer (n=3). Our study included also 3 cases with 
no detectable cervical pathology (healthy donors, n=3), although they 
had a positive HPV test. The socio-demographic and clinical data of 
the study population relevant to the main risk factors associated with 
cervical cancer carcinogenesis, such as age, number of sexual partners, 
number of pregnancies and history of genital infection are summarized 
in the supplementary table 2. The presence of HR and LR-HPV types in 
the cervical swabs was analyzed by multiplex PCR genotyping (MPG), 
a highly sensitive technique described elsewhere [13]. The results 
are shown in the supplementary table 3. HPV was detected in all the 
patients as well as the healthy donors participating in the study. HPV16 
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and HPV18 were the most prevalent virus types (n=19, 95%). In 3 
cases these viruses co-existed with LR-HPV types and only one case 
was associated with HR-HPV types other than HPV16 and HPV18. 
The number of copies of the respective E7 transcripts was estimated by 
quantitative RT-PCR. In the samples of all healthy donors and in nearly 
half of the patients the number of copies was below 50. In the rest the 
copy number ranged from 50-100 (Supplementary table 3).
Genome-wide promoter methylation analysis
Methylation changes in promoter sequences has often been linked 
to abnormal transcriptional activity. About half of the known human 
gene promoters contain CpG islands [22], which are protected from 
de novo methylation in normal tissues, but often acquire methylation 
in cancer cells that eventually leads to gene silencing. In order to 
understand the global changes in methylation that occur during 
cervical cancer progression and their effects on transcription, we 
performed a genome-wide DNA methylation profiling of 27578 CpG 
dinucleotides, located in the promoter region of 14495 genes, using 
total DNA extracted from cervical swabs of cervical dysplasia (CIN 
I-CIN III) and cervical cancer patients, as well as healthy donors. The 
dataset generated can be retrieved from the Gene Expression Omnibus 
(accession number GSE41384).
To capture the intrinsic nature of the data, statistical analyses 
were performed by means of unsupervised hierarchical clustering. We 
decided to exclude one CIN I sample, because it presented a markedly 
different behavior with respect to the rest of samples. Unsupervised 
analysis (Hierarchical Clustering) uncovered that the samples tend to 
cluster into two groups based on the similarity (measured in Euclidian 
distances) of methylation profiles: Group A, comprising samples 
negative for intraepithelial lesion, as well as CIN I and CIN II samples; 
and Group B, including CIN III, carcinoma in situ and invasive cancer 
samples. In a second step, supervised T-Test analysis was performed to 
identify genes with significant differences in their methylation levels 
between the groups detected in the unsupervised analysis. This analysis 
showed that, during cervical cancer progression, hypermethylation of 
CpG islands within gene promoters is significantly more frequent than 
hypomethylation (Figure 1A). Thus, CpG islands in the promoters of 
1069 genes were hypermethylated in the group B, while a remarkably 
lower number of genes (85) were hypomethylated in this group 
(p<0.0001) (Figure 1A and Supplementary table 4). The heatmap in 
figure 1A illustrates the differential methylation of gene promoters in 
healthy/CIN I/CIN II samples compared with those in CIN III/cervical 
cancer samples. The complete list of the 1069-hypermethylated genes 
arranged by their ∆ß-values is shown in the supplementary table 4 
together with their fold-change and the p-values for the Student t-test 
applied to the statistic analysis of the data. 
The table 1 displays a list of the 40 genes with the highest ∆ß-values 
in CIN III and cervical cancer (group B). The criteria for selection of 
these genes were: (i) a mean basal ß-value < 0.2 in group A (healthy/CIN 
I/CIN II samples) and (ii) a ∆ß-value > 0.45 (calculated by subtracting 
the mean ß-values in the group A from those in group B). The three top 
genes in this list are IGSF21, UTF1 and PTGDR with ∆ß-values of 0.59, 
0.57 and 0.55, respectively. This approach also revealed six genes with 
a fold change in methylation > 10: UTF1, CADPS, ELMO1, ZNF132, 
NELL1 and SLC18A3. 
In order to compare and integrate the genes differentially methylated 
in our study population with gene expression profiles described 
previously in cervical cancer samples, we selected and analyzed a 
number of gene expression microarrays of public access [19]. The 
microarray platform used was the Affymetrix HG-U133A in the Gene 
Expression Omnibus (GEO, www.ncbi.nlm.nih.gov/geo/) accession 
number GSE780319. The selection of differentially expressed genes 
was performed with an unsupervised cluster analysis with Euclidian 
distance. The analysis was performed using the same software as for 
the methylation microarrays to compare gene expression in cervical 
cancer and normal cervical samples and applying the same cut-off for 
statistical significance (p≤0.0001).
The figure 1B and C shows the result of such analysis, by which 
1726 genes were found down-regulated in cervical cancer compared 
with normal cervical tissue. When these genes were confronted with 
the 1069 with hypermethylated promoters, we identified a set of 132 
genes (12.3%) common to both groups (Figure 1C, Supplementary 
table 5). The heatmap in figure 1B shows a supervised hierarchical 
clustering of the hypermethylated genes whose expression was lower in 
cervical cancer compared to normal cervical tissue. The table 2 contains 
data of the 40 genes with the highest degree of promoter methylation 
(∆ß-values between 0.53 and 0.18, fold change ranging between 9.74 
and 4.06) and with the lowest expression level (fold change between 
-2.18 and -2.07) in CIN III and cervical cancer compared to normal 
cervical tissue. The top three genes in this list are: FLT4 (Fms-related 
tyrosine kinase 4), EPB41L3 (erythrocyte membrane protein band 
4.1L3), FGF4 (Fibroblast growth factor 4), with ∆ß-values of 0.53, 0.49 
and 0.48, respectively. 
As shown in the figure 1 our analysis uncovered also 85 
hypomethylated genes (Supplementary table 6). The Table 3 contains 
the data of a selection of 40 genes with lower degree of promoter 
methylation in CIN III and cervical cancer and with the highest 
-∆ß-values (-0.24 to -0.10). There are six genes with a -∆ß of -0.20 
or above: FAM217B (family with sequence similarity 217 member 
B), of unknown function, UPB1 (beta-ureidopropionase 1), STXBP2 
(syntaxin binding protein 2), FAM173A, CHRD (chordin) and VHL 
(von Hippel-Lindau tumor suppressor). Furthermore, our supervised 
T-test analysis revealed 1945 genes with augmented expression 
in cervical cancer compared to normal tissue. In contrast to the 
hypermethylated genes, contingency tables showed that only as few as 
4 out of the 85-hypomethylated genes (4.7%) were in the group of genes 
with increased expression in cervical cancer: NCAP-G (a subunit of the 
condensin complex), PSENEN (presenilin gamma-secretase subunit), 
HIST1H3H (Histone cluster 1 H3 family member H) and RRM2 
(Ribonucleotide reductase regulatory subunit M2) with -∆ß-values of 
-0.05, -0.12, -0.07 and -0.18, respectively (Table 3 and supplementary 
table 6).
Differentially methylated functional gene clusters in 
neoplastic cervical lesions
Gene ontology analysis of CpG islands at promoter regions 
displaying significantly higher methylation profiles in advanced 
cervical lesions and cervical cancer compared to low-grade lesions and 
normal tissue revealed several gene clusters. 
We used the bioinformatics tool Database for Annotation, 
Visualization and Integrated Discovery (DAVID) [17] (URL david.
abcc.ncifcrf.gov) for the analysis of  genes based on Gene Ontology 
(GO). To analyze the hyper and hypomethylated genes whose heat 
map is shown in figure 1, we applied the Functional Annotation Tool of 
DAVID, which provides information on biological functions enriched 
in a gene list relative to all annotated genes. 
The left panel in figure 2 (A and B) shows the GO-analysis of the 
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Figure 1. Clustering analysis of methylation and correlation between hypermethylation and gene expression in a subset of 132 genes. A. Supervised hierarchical clustering of gene promoter 
methylation in cervical samples from CIN, carcinoma in situ and invasive cancer patients as well as healthy donors. Differentially methylated genes were identified by a supervised T-Test 
analysis in which only those with a p≤0.0001 were selected. The heatmap of the methylation values discriminates between two subsets of cervical samples: normal and low-grade lesions 
(CIN I and CIN II), on the left side, and CIN III/cancer (in situ and invasive) on the right side of the panel. The intensity of the colors represents the gradient of the ∆β-values, ranging from 
0 (bright green) to 1 (bright red). The results suggest that the promoter regions of these genes are sites of increased methylation heterogeneity in advanced cervical dysplasia and cancer. 
B. Heatmap from a supervised hierarchical clustering of 132 hypermethylated genes with down-regulated expression in cervical cancer compared to normal tissue. Patients from GSE7803 
were included. A T-test analysis with p=0.0001 as cut-off was used. The intensity of the colors represents the gradient of expression ranging from 0 (bright green) to 1 (bright red).  C. Venn 
Diagram of contingency showing an overlapping group of hypermethylated and down-regulated genes in CIN III and cervical cancer (p<0.0001).
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CpG ID Gen Description RefSeq Entrez
Group A Group B
∆-β Fold Change
Adjusted 
p valueMean SD Mean SD
cg23349790 IGSF21 immunoglobin superfamily member 21 NM_032880.2 84966 0.10 0.08 0.70 0.19 0.59 6.72 5.60E-6
cg09053680 UTF1 undifferentiated embryonic cell transcription factor 1 NM_003577.2 8433 0.06 0.08 0.63 0.20 0.57 10.44 1.21E-5
cg09516965 PTGDR prostaglandin D2 receptor NM_000953.2 5729 0.17 0.28 0.72 0.21 0.55 4.13 2.07E-4
cg08185661 SYT9 synaptotagmin 9 NM_175733.2 143425 0.09 0.08 0.63 0.17 0.54 7.38 5.81E-6
cg04534765 GALR1 galanin receptor 1 NM_001480.2 2587 0.10 0.08 0.64 0.19 0.54 6.49 1.38E-5
cg01009664 TRH thyrotropin releasing hormone NM_007117.1 7200 0.12 0.08 0.65 0.13 0.54 5.69 1.83E-7
cg17861230 PDE4C phosphodiesterase 4C NM_000923.1 5143 0.15 0.08 0.69 0.14 0.54 4.58 2.45E-7
cg21458907 CADPS calcium dependent secretion activator NM_183393.1 8618 0.06 0.04 0.59 0.18 0.54 10.29 2.69E-5
cg25437385 SLC35F3 solute carrier family 35 member F3 NM_173508.1 148641 0.08 0.05 0.62 0.11 0.54 7.58 2.83E-8
cg00489401 FLT4 fms related tyrosine kinase 4 NM_182925.1 2324 0.10 0.06 0.64 0.19 0.53 6.13 1.83E-5
cg18443378 WDR17 WD repeat domain 17 NM_181265.2 116966 0.08 0.09 0.61 0.17 0.53 7.38 5.36E-6
cg11657808 RYR2 ryanodine receptor 2 NM_001035.1 6262 0.11 0.10 0.64 0.20 0.53 5.69 2.36E-5
cg08453021 ELMO1 engulfment and cell motility 1 NM_014800.8 9844 0.04 0.02 0.56 0.15 0.51 12.65 6.10E-6
cg08575537 EPO erythropoietin NM_000799.2 2056 0.16 0.10 0.67 0.16 0.51 4.29 1.67E-6
cg07017374 FLT3 fms related tyrosine kinase 3 NM_004119.1 2322 0.09 0.09 0.59 0.19 0.51 6.93 1.79E-5
cg11438428 PTF1A pancreas specific transcription factor, 1a NM_178161.1 256297 0.12 0.05 0.62 0.15 0.51 5.26 4.75E-6
cg26609631 GSX1 GS homeobox 1 NM_145657.1 219409 0.12 0.10 0.62 0.15 0.50 5.30 1.10E-6
cg02164046 SST somatostatin NM_001048.3 6750 0.08 0.03 0.58 0.20 0.50 6.91 6.56E-5
cg26128092 WRAP73 WD repeat containing, antisense to TP73 NM_017818.2 49856 0.09 0.05 0.58 0.17 0.50 6.77 1.32E-5
cg00027083 EPB41L3 erythrocyte membrane protein band 4.1 like 3 NM_012307.2 23136 0.13 0.14 0.62 0.12 0.49 4.73 3.89E-7
cg13877915 ZNF132 zinc finger protein 132 NM_003433.2 7691 0.05 0.07 0.54 0.20 0.49 10.02 1.52E-4
cg22619018 CSMD1 CUB and Sushi multiple domains 1 NM_033225.3 64478 0.11 0.09 0.60 0.24 0.49 5.53 2.99E-4
cg22881914 NID2 nidogen 2 NM_007361.2 22795 0.13 0.14 0.61 0.24 0.49 4.81 2.10E-4
cg19831575 FGF4 fibroblast growth factor 4 NM_002007.1 2249 0.08 0.06 0.57 0.24 0.48 6.90 3.71E-4
cg01805540 CACNB2
calcium voltage-gated 
channel auxiliary subunit 
beta 2
NM_201593.1 783 0.07 0.06 0.55 0.20 0.48 8.44 6.42E-5
cg17371081 NELL1 neural EGFL like 1 NM_006157.2 4745 0.05 0.04 0.54 0.25 0.48 10.39 4.37E-4
cg03544320 CRMP1 collapsin response mediator protein 1 NM_001313.3 1400 0.25 0.19 0.73 0.10 0.48 2.95 7.08E-6
cg25302419 CTNND2 catenin delta 2 NM_001332.2 1501 0.07 0.07 0.56 0.18 0.48 7.55 2.37E-5
cg07533148 TRIM58 tripartite motif containing 58 NM_015431.2 25893 0.06 0.06 0.54 0.25 0.48 8.76 5.59E-4
cg09551147 SORCS3 sortilin related VPS10 domain containing receptor 3 NM_014978.1 22986 0.05 0.04 0.53 0.24 0.47 9.89 3.78E-4
cg12128017 EPHA10 EPH receptor A10 NM_173641.1 284656 0.08 0.05 0.55 0.18 0.47 7.15 6.94E-5
cg20291049 POU3F3 POU class 3 homeobox 3 NM_006236.1 5455 0.16 0.09 0.64 0.18 0.47 3.88 1.74E-5
cg19096475 CLMP CXADR like membrane protein NM_024769.2 79827 0.11 0.05 0.58 0.14 0.47 5.27 2.89E-6
cg11389172 SLC18A3 solute carrier family 18 member A3 NM_003055.1 6572 0.05 0.04 0.52 0.24 0.47 11.29 3.67E-4
cg10303487 DPYS dihydropyrimidinase NM_001385.1 1807 0.09 0.07 0.56 0.20 0.47 6.31 8.38E-5
cg19064258 HS3ST2 heparan sulfate-glucosamine 3-sulfotransferase 2 NM_006043.1 9956 0.11 0.06 0.58 0.18 0.47 5.14 3.08E-5
cg27403635 KCNN2
potassium calcium-activated 
channel subfamily N member 
2
NM_021614.2 3781 0.09 0.09 0.56 0.15 0.47 6.14 3.51E-6
cg15747595 TSPYL5 TSPY like 5 NM_033512.2 85453 0.14 0.08 0.60 0.15 0.47 4.44 2.12E-6
cg06722633 GRIK3
glutamate ionotropic 
receptor kainate type 
subunit 3
NM_000831.2 2899 0.12 0.10 0.59 0.21 0.47 4.80 7.96E-5
cg17525406 AJAP1 adherens junctions associated protein 1 NM_018836.2 55966 0.12 0.08 0.59 0.24 0.47 4.89 4.04E-4
Table 1. Data on selected genes with higher degree of methylation, irrespective of their expression status, in cervical swabs of CIN III/cervical cancer patients compared with CIN I/CIN 
II patients and healthy donors. 
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Gene Description RefSeq Entrez ID









p valueMean SD Mean SD
FLT4 Fms-related tyrosine kinase 4 NM_182925.1 2324 0.10 0.06 0.64 0.19 0.53 6.13 -2.02 1.83E-5
EPB41L3 erythrocyte memb. protein band 4.1L3 NM_012307.2 23136 0.13 0.14 0.62 0.12 0.49 4.73 -2.12 3.89E-7
FGF4 Fibroblast growth factor 4 NM_002007.1 2249 0.08 0.06 0.57 0.24 0.48 6.9 -2.02 3.71E-4
HTR4 5-hydroxytryptamine receptor 4 NM_000870.2 3360 0.08 0.04 0.55 0.15 0.46 6.6 -2.04 2.15E-5
EDN3 Endothelin 3 NM_000114.2 1908 0.08 0.06 0.52 0.20 0.44 6.79 -2.52 1.23E-4
SLC6A2 Solute carrier family 6 member 2 NM_001043.2 6530 0.05 0.04 0.49 0.24 0.43 9 -2.04 6.63E-4
ZNF134 Zinc finger protein 134 NM_003435.2 7693 0.09 0.06 0.52 0.20 0.43 5.57 -2.07 1.76E-4
GRM6 glutamate receptor, metabotropic 6 NM_000843.2 2916 0.12 0.06 0.54 0.23 0.42 4.6 -2.07 4.23E-4
BCAN brevican NM_198427.1 63827 0.10 0.03 0.51 0.23 0.41 5.23 -2.03 6.72E-4
CDO1 Cysteine dioxygenase, type I NM_001801.2 1036 0.05 0.05 0.45 0.21 0.40 8.9 -2.04 5.22E-4
ZNF671 Zinc finger protein 671 NM_024833.1 79891 0.06 0.06 0.46 0.26 0.40 7.38 -2.05 0.001
PENK Proenkephalin NM_006211.2 5179 0.04 0.03 0.43 0.21 0.39 9.74 -2.18 6.68E-4
EPHA5 EPH receptor A5 NM_182472.1 2044 0.10 0.06 0.49 0.19 0.39 4.7 -2.04 2.35E-4
SLC27A6 Solute carrier family 27 NM_014031.3 28965 0.08 0.05 0.46 0.24 0.38 5.95 -2.11 0.001
COL6A2 Collagen type VI alpha 2 NM_001849.2 1292 0.04 0.03 0.42 0.25 0.37 9.66 -2.02 0.002
AK5 Adenylate kinase 5 NM_174858.1 26289 0.07 0.05 0.44 0.20 0.37 6.57 -2.02 5.79E-4
PTPRN Protein tyrosine phosphatase receptor NM_002846.2 5798 0.07 0.06 0.43 0.23 0.37 6.49 -2.04 0.002
PHOX2A Paired-like homeobox 2A NM_005169.2 401 0.07 0.06 0.42 0.23 0.36 6.27 -2.03 0.001
CDH8 Cadherin 8, type 2 NM_001796.2 1006 0.06 0.04 0.40 0.16 0.34 6.6 -2.05 2.63E-4
GAS7 Growth arrest-specific 7 NM_003644.2 8522 0.07 0.11 0.41 0.28 0.34 5.62 -2.18 0.007
SFRP1 secreted frizzled-related protein 1 NM_003012.3 6422 0.09 0.07 0.44 0.27 0.34 4.63 -2.09 0.005
HYDIN hydrocephalus inducing homolog NM_017558.2 54768 0.09 0.06 0.42 0.19 0.34 4.77 -2.02 6.49E-4
FAM163A
Family with sequence 
similarity 163 
member A





NM_024893.1 79953 0.07 0.05 0.40 0.20 0.33 5.47 -2.04 0.001
CACNA1G Calcium channel voltage-dependent 1G NM_018896.3 8913 0.05 0.05 0.37 0.21 0.32 7.23 -2.07 0.002
EDNRB Endothelin receptor type B NT_024524.13 1910 0.04 0.03 0.35 0.17 0.32 9.23 -2.1 5.70E-4
CXCL12 chemokine (C-X-C motif) ligand 12 NM_199168.2 6387 0.09 0.05 0.41 0.16 0.32 4.68 -2.4 3.14E-4
RAX retina & anterior neural fold homeobox NM_013435.1 30062 0.07 0.02 0.40 0.23 0.32 5.37 -2.04 0.003
CDX2 Caudal type homeobox 2 NM_001265.2 1045 0.06 0.03 0.37 0.14 0.30 5.89 -2.04 2.58E-4
PRMT8 Protein arginine methyltransferase 8 NM_019854.3 56341 0.04 0.04 0.34 0.20 0.30 8.67 -2.03 0.002
DOK5 Docking protein 5 NM_018431.3 55816 0.07 0.03 0.36 0.18 0.29 5.39 -2.05 0.001
PDGFD platelet derived growth factor D NM_025208.3 80310 0.07 0.08 0.35 0.22 0.29 5.33 -2.35 0.004
ZNF549 Zinc finger protein 549 NM_153263.1 256051 0.05 0.05 0.34 0.19 0.29 6.7 -2.03 0.002
GABRA2 Gamma-aminobutyric acid A2 NM_000807.1 2555 0.06 0.06 0.34 0.22 0.28 5.49 -2.03 0.006
Table 2. Data on selected genes whose promoter regions had a higher degree of methylation and their expression was diminished in CIN III/cervical cancer compared with CIN I/CIN II and 
healthy donor samples. The table shows the 40 genes with the highest degree of methylation (∆ß-values between 0.59 and 0.47, fold change between 9.74 and 4.06) and the lowest expression 
level (fold change between -2.18 and -2.07) in CIN III and cervical cancer compared to normal cervical tissue.
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CpG ID Gene Description RefSeq Entrez
Group A Group B
∆-β Fold Change
Adjusted 
p valueMean SD Mean SD
cg00400263 FAM217B family with sequence similarity 217 member B NM_022106.1 63939 0.89 0.09 0.65 0.19 -0.24 0.73 0.006
cg17647273 UPB1 beta-ureidopropionase 1 NM_016327.2 51733 0.86 0.07 0.63 0.16 -0.24 0.73 0.002
cg21541083 STXBP2 syntaxin binding protein 2 NM_006949.1 6813 0.85 0.08 0.62 0.11 -0.23 0.73 2.29E-04
cg09830866 FAM173A family with sequence similarity 173 member A NM_023933.1 65990 0.71 0.11 0.49 0.11 -0.22 0.68 3.54E-04
cg25182621 CHRD chordin NM_177978.1 8646 0.83 0.06 0.63 0.13 -0.20 0.76 0.001
cg16869108 VHL von Hippel-Lindau tumor suppressor NT_022517.17 7428 0.68 0.13 0.48 0.10 -0.20 0.71 0.002
cg08124030 TM4SF1 transmembrane 4 L six family member 1 NM_014220.2 4071 0.71 0.13 0.53 0.15 -0.19 0.74 0.009
cg18623836 RRM2 ribonucleotide reductase regulatory subunit M2 NM_001034.1 6241 0.64 0.13 0.47 0.08 -0.18 0.73 0.003
cg18149919 PUF60 poly(U) binding splicing factor 60 NM_014281.3 22827 0.83 0.06 0.65 0.09 -0.17 0.79 4.04E-04
cg13625403 TRIM29 tripartite motif containing 29 NM_058193.1 23650 0.85 0.10 0.68 0.12 -0.17 0.80 0.004
cg02601403 TBC1D3C TBC1 domain family member 3C NM_001001418.2 414060 0.83 0.06 0.66 0.07 -0.17 0.80 0.007
cg02910574 CHMP1A charged multivesicular body protein 1A NM_002768.1 5119 0.80 0.11 0.64 0.10 -0.16 0.80 0.004





NM_207392.1 388533 0.58 0.14 0.43 0.07 -0.15 0.74 0.009
cg23667432 ALPP alkaline phosphatase, placental NM_001632.2 250 0.62 0.11 0.47 0.06 -0.15 0.76 0.002
cg24691461 CCM2L CCM2 like scaffolding protein NM_080625.2 140706 0.57 0.13 0.43 0.06 -0.14 0.75 0.009





NM_001003931.1 10039 0.59 0.09 0.46 0.09 -0.13 0.77 0.004
cg19946699 SH3BGR SH3 domain binding glutamate rich protein NM_007341.2 6450 0.53 0.10 0.40 0.07 -0.13 0.75 0.003
cg21372914 CLEC4M C-type lectin domain family 4 member M NM_014257.3 10332 0.79 0.04 0.66 0.11 -0.13 0.83 0.006
cg02089348 TMEM129 transmembrane protein 129 NM_138385.2 92305 0.45 0.06 0.33 0.10 -0.13 0.72 0.005
cg09547190 CARD19
caspase recruitment 
domain family member 
19
NM_032310.2 84270 0.52 0.08 0.39 0.06 -0.13 0.76 0.001
cg14757296 HYAL1 hyaluronoglucosaminidase 1 NM_007312.3 3373 0.89 0.03 0.76 0.10 -0.12 0.86 0.007
cg17839611 GNGT2 G protein subunit gamma transducin 2 NM_031498.1 2793 0.71 0.10 0.59 0.05 -0.12 0.83 0.003
Table 3. Data on selected genes with lower degree of methylation in cervical swabs of CIN III/cervical cancer patients compared with CIN I/CIN II patients and healthy donors. The table 
shows the 40 genes with the lowest degree of methylation in CIN III and cervical cancer compared to normal cervical tissue.
HAND1 heart & neural crest derivatives expr.1 NM_004821.1 9421 0.07 0.03 0.34 0.24 0.28 5.17 -2.05 0.008
STAC SH3 and cysteine rich domain NM_003149.1 6769 0.05 0.03 0.32 0.17 0.27 6.75 -2.04 0.001
GRIK1 glutamate receptor ionotropic kainate 1 NM_000830.3 2897 0.06 0.04 0.32 0.20 0.26 5.24 -2.03 0.005
ADRA2A adrenergic alpha-2A-receptor NM_000681.2 150 0.06 0.07 0.31 0.18 0.25 4.85 -2.1 0.003
COL14A1 collagen type XIV alpha 1 NM_021110.1 7373 0.05 0.04 0.27 0.16 0.22 5.22 -2.29 0.003
MYRIP Myosin VIIA and Rab interacting prot. NM_015460.2 25924 0.03 0.03 0.21 0.11 0.18 6.76 -2.03 0.002
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cg13888886 SPO11
SPO11, initiator of 
meiotic double stranded 
breaks
NM_012444.2 23626 0.89 0.04 0.77 0.09 -0.12 0.86 0.004






NM_024111.2 79094 0.84 0.04 0.72 0.08 -0.12 0.86 0.002
cg15952487 CD1B CD1b molecule NM_001764.1 910 0.52 0.09 0.41 0.07 -0.12 0.78 0.006
cg25076881 OR10J1 olfactory receptor family 10 subfamily J member 1 NM_012351.1 26476 0.46 0.11 0.34 0.05 -0.12 0.75 0.009
cg11536940 CPQ carboxypeptidase Q NM_016134.2 10404 0.24 0.09 0.13 0.05 -0.11 0.53 0.004
cg23228178 PADI4 peptidyl arginine deiminase 4 NM_012387.1 23569 0.53 0.08 0.42 0.07 -0.11 0.79 0.004
cg00136477 C1QC complement C1q C chain NM_172369.2 714 0.70 0.07 0.59 0.07 -0.11 0.84 0.002
cg17676574 UROC1 urocanate hydratase 1 NM_144639.1 131669 0.77 0.07 0.66 0.06 -0.11 0.86 0.001
cg00750606 CDA cytidine deaminase NM_001785.1 978 0.67 0.05 0.56 0.05 -0.11 0.84 3.46E-04
cg24387380 GABRA5
gamma-aminobutyric 
acid type A receptor 
alpha5 subunit
NM_000810.2 2558 0.58 0.10 0.47 0.06 -0.11 0.81 0.009
cg01618851 CD209 CD209 molecule NM_021155.2 30835 0.54 0.07 0.43 0.06 -0.11 0.80 0.003
cg11299964 MAPKAP1
mitogen-activated 
protein kinase associated 
protein 1
NM_001006620.1 79109 0.27 0.09 0.17 0.05 -0.11 0.61 0.006
cg06256735 MFAP5 microfibrillar associated protein 5 NM_003480.2 8076 0.71 0.08 0.61 0.06 -0.11 0.85 0.006
cg23988567 IGHG3 immunoglobulin heavy constant gamma 3 NT_026437.13 3502 0.82 0.03 0.71 0.09 -0.11 0.87 0.009
cg26799474 CASP8 caspase 8 NM_001228.3 841 0.32 0.09 0.21 0.06 -0.10 0.67 0.007
132 genes with higher degree of promoter methylation in CIN III / 
cervical cancer irrespective of the gene expression data, These genes 
were selected as the first 132 genes in the list of hypermethylated genes 
arranged by their ∆ß-values (Supplementary table 4). The results, 
after applying REVIGO [18] to eliminate redundant terms, showed a 
higher frequency of transcription and cell structure genes (27% and 
26%, respectively), followed by genes involved in neuronal activity, 
signal transduction, cell cycle and metabolism (14%, 12% 8% and 8%, 
respectively). An interactive graph of biological processes based on the 
GO analysis is shown in figure 2 B.
The right panel in figure 2 (C and D) shows the GO-analysis of the 
132 genes hypermethylated and down-regulated in CIN III / cervical 
cancer, after applying REVIGO [18] to eliminate redundant terms, 
showed a prevalence of genes involved in cell structure (27.4%), followed 
by genes related to transcription (24.3%), metabolism (10%), neuronal 
function (6.8%), cell cycle regulation (5.7%), development (4.1%) and 
other cellular processes such as regulation of T cell activation, ion 
transport and cell adhesion (Figure 2 C and D). The figure 2 C shows 
an Interactive graph of biological processes based on the ontology 
analysis and the gene clusters of the 132 hypermethylated and down-
regulated genes. The nodes with higher gene representation are related 
to proliferation, signaling, adhesion and cell-cell communication.
The figure 3 shows the GO enrichment analysis of the 85 genes with 
a lower degree of methylation in CIN III / cervical cancer. The fraction 
distribution of these genes (Figure 3 A) shows a higher incidence of genes 
related to cell structure (22%) and metabolism (13%), but significantly 
less genes involved in transcription regulation (8%) than in the group 
of hypermethylated genes. Cell cycle and development genes represent 
6% each. In addition, a large proportion of genes (34%) are involved 
in a variety of functions, such as apoptosis, organelle organization and 
secretion, ion and sugar transport and regulation of immune responses. 
The four hypomethylated genes with enhanced expression in CIN III / 
cervical cancer are basically involved in regulation of gene expression 
and signal transduction.
Genes with apparent correlation between promoter 
methylation status and gene expression
An interesting group of genes that were hypermethylated in our 
study, and whose expression was previously found diminished in 
cervical cancer, belonged to the cadherin family. Thus, we found 
hypermethylated genes encoding cell adhesion proteins, such as 
PCDH11X, CDH22, CDH12 and CDH8. Previous methylation studies 
using MeDIP-chip analysis showed that the promoter of PCDH11X was 
hypermethylated in CIN III [23]. Also the promoter of CDH22 has been 
reported hypermethylated in breast cancer tissue compared to adjacent 
normal tissue. In addition, hypermethylation of CDH22 correlated 
with poor prognosis regardless of age and tumor stage [24]. Our 
results confirm these data and extend them to increased methylation of 
cadherin CDH12 in CIN III and cervical cancer. CDH12 is a large gene 
located in chromosome 5p14.3 close to FRA5E, a region of genomic 
instability, which belongs to a group of about 90 common fragile sites 
(CFS) distributed throughout the human genome, where oncogenic 
HPVs frequently integrate [22]. Hypermethylation of CDH12 might 
be related to HPV integration, although this event remains to be tested 
in our samples. In agreement with our data, a recent prospective 
cross-sectional study, showed promoter hypermethylation of cadherin 
8, type 2 (CDH8) and another two tumor-suppressor candidate 
genes (adenylate cyclase 8, ADCY8, and zinc finger protein 582, 
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Figure 2. Gene ontology (GO) enrichment analysis of the genes with higher methylation in CIN III and cervical cancer compared with CIN I/CIN II and healthy donor samples. A and B 
show the analysis of 132 genes with hypermethylated promoter region in CIN III and cervical cancer. C and D show the analysis of genes with hypermethylated promoter region associated 
with diminished expression in CIN III and cervical cancer. A and C: Fraction distribution generated with Panther of GO terms based on molecular function, biological process and cellular 
component. B and D: Analysis in GO terms plotted following REVIGO protocols resulting in an interactive graph of biological process based on the ontology analysis and the gene clusters 
of the hypermethylated and down-regulated genes. The size and color intensity of the nodes are proportional to the number of genes associated with the specific term and the statistical 
significance (p value), respectively. The thickness of the lines joining the nodes is proportional to the proximity of the regulatory or biochemical pathways in which they interact.
ZNP528), as quantified by bisulfite-pyrosequencing of genomic DNA. 
Hypermethylation of these genes correlated with worsening grade [26].
The gene EDN3 (endothelin 3), encoding a vasoactive peptide, 
was hypermethylated in CIN III/cancer samples. This gene has been 
recently reported hypermethylated and down-regulated in CIN III 
lesions suggesting its involvement in the pathogenesis of cervical cancer 
[27,28]. Interestingly, the gene encoding the endothelin receptor type 
B (EDNRB) was also hypermethylated in CIN and cancer tissues in a 
recent study [29].
We also identified members of the SFRP family hypermethylated 
in CIN III and cervical cancer, in particular SFRP1 (Secreted Frizzled 
Related Protein 1), which acts as modulator of Wnt signaling through 
direct interaction with Wnt family members. Epigenetic silencing of 
SFRP genes leads to deregulated activation of the Wnt-pathway, which 
is associated with cancer. SFRP1 was previously found hypermethylated 
and silenced in invasive cervical cancer [30] and cervical cancer-
derived cell lines [31]. 
The TP73 gene is homologous to p53 gene, involved in cell cycle 
control in response to DNA damage, TP73 was hypermethylated in CIN 
III and cancer in the present study, correlating with lower expression in 
cervical cancer, similar to results reported previously [32,33]. 
The AR (androgen receptor) gene, which has been reported 
underexpressed in CIN III/cervical cancer compared to CIN I/CIN II 
[34], was differentially methylated in these two groups with increasing 
methylation during progression from CIN I to cancer. 
Some genes related to the immune system, such as CXCL12 and IL1b, 
were hypermethylated in CIN III and cervical cancer. Recently, CXCL12 
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has been shown hypermethylated in cervical cancer biopsies and in 
established cell lines (HeLa, SiHa) and its expression down regulated [35].
Discussion
There is an imperative demand for the identification of markers 
that enable predict progression of cervical intraepithelial neoplasia 
to invasive cancer, thus providing better support for decisions on the 
follow up and handling of this disease, especially at the pre-cancer 
stages. Biomarkers associated with DNA methylation are revealing 
promising11. DNA methylation is a normal cellular process used 
to silence genes and regulate gene dosage. Yet aberrations in DNA 
methylation, most notably in gene promoter regions, have been 
observed in the process of carcinogenesis from tumor initiation to 
metastasis [36]. Indeed, differential methylation and, in particular, 
hypermethylation has been frequently described in many types of 
tumors with respect to the tissues from which they originate [37].
This study was aimed at identifying gene promoter regions 
differentially methylated in samples of patients with either advanced 
precursor intraepithelial lesions or cervical cancer as compared to 
samples of healthy donors with no evidence of cervical pathology. 
In addition, we intended to determine whether the changes in gene 
promoter methylation were correlated with differential expression of 
the corresponding encoded proteins during cervical cancer progression.
Previous studies evaluating cervical cancer epigenetics have 
shown differential methylation of the promoter region of specific 
genes in normal and cervical cancer tissues [30]. Indeed, aberrant 
methylation has been described from the very early stages of cervical 
carcinogenesis. Besides their mechanistic implications, the genes that 
are differentially methylated in tumor cells may serve as biomarkers 
for early detection of the disease as well as be of prognostic value [38]. 
However, studies available to date reveal somehow inconclusive and, 
in some cases, conflicting results [10]. This could be explained by the 
different analytical techniques employed, the ethnic/genetic variability 
of the populations under study, differences in the HPV types present 
in the samples, and also the diversity of genes evaluated in such studies 
[39]. Some of these genes were CDH1 (E-cadherin), DAPK1 (death-
associated protein kinase 1), CADM1 (cell adhesion molecule 1), 
RARB and TERT (telomerase). In general, these studies described 29 to 
33% methylation in samples with high-grade cervical lesions (CIN II / 
CIN III) related with progression to cervical cancer, without reaching 
a conclusion on the possible predictive potential in cervical cancer 
progression [10].
It has become evident, however, that only a wide simultaneous 
analysis of the genome may allow identify subsets of differentially 
methylated genes associated with the development of cervical cancer, 
which could be of high prognostic significance. These studies should 
provide new data on patterns of DNA methylation associated with 
cervical cancer progression, thereby increasing the number of candidate 
genes that could serve as prognostic biomarkers.  In a previous study 
analyzing the genome-wide methylation pattern of high-grade (CIN 
III) and healthy women, COL25A1 and KATNAL2 were identified as 
hypermethylated and were suggested as candidate biomarkers for early 
detection of cervical cancer [23]. Furthermore, in a more recent study, 
Farkas et al. [38] described a subset of 24 differentially methylated genes 
in cervical cancer compared with CIN3 and normal cervical tissue. 
In the present study we used the Illumina platform to evaluate 
the methylation profiles of the genomes of cervical swabs of patients 
at various stages of cervical carcinogenesis (CIN I to CIN III and 
cervical cancer) and compared them with those of healthy donors. The 
results were examined applying an unsupervised cluster analysis which 
allowed identify two distinct methylation profiles, one corresponding 
to healthy donor, CIN I and CIN II (group A) and another to CIN III 
and cervical cancer (group B). Due to the limited number of samples, 
it was not possible to assess a statistically significant relationship 
between the HPV type (and copy number) and the methylation status 
of individual genes within the two groups. 
Hypermethylation frequently leads to down-regulation of gene 
expression. DNA-binding proteins containing methyl-CpG binding 
domains or C2H2 zinc fingers bind to methylated DNA and mediate 
transcriptional repression of methylated promoters [40]. Therefore, 
we considered essential to compare the genes that we found to have 
hypermethylated promoters in the group CIN III/cervical cancer 
patients with the expression profile of these genes in a gene expression 
analysis performed in a comparable study population using a 
microarray platform (Affymetrix HG-U133A). In this cross-analysis 
we found that, of the 1069 hypermethylated genes that we identified, 
only the expression of 120 genes (~11%) was down-regulated in the 
Figure 3. GO enrichment analysis of the 85 hypomethylated genes in CIN III and cervical cancer. A. Fraction distribution generated with Panther of hypomethylated genes GO terms 
based on molecular function, biological process and cellular component. B. Analysis in GO terms plotted following REVIGO protocols. Interactive graph of biological process based on 
the ontology analysis and the gene clusters of the hypomethylated genes. The size of the nodes are proportional to the number of genes associated with the specific term and the statistical 
significance (p value), respectively. The thickness of the lines joining the nodes is proportional to the proximity of the regulatory or biochemical pathways in which they interact.
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Affymetrix HG-U133A gene expression array, while the expression of the 
remainder hypermethylated genes did not change (Figure 1 and table 2).
The majority of hypermethylated and down-regulated genes 
identified in the present study are involved in cellular transcription and 
transduction pathways, only a few are involved in metabolism and cell 
adhesion. From the known functions of these genes it can be inferred 
that their repression would facilitate the process of carcinogenesis 
[41]. The analysis of the genes found differentially hypomethylated 
in the present study pinpointed four genes that have been found 
overexpressed in CC: HCAP-G, PSEN, HIST1H3H and RRM2. 
Increased transcription of the genes AKR1B10 genes, TPX2, HCAP-G 
and RRM2 has been described previously in hepatocellular carcinoma 
[42]. In addition, it has been shown that E7 increases the expression of 
RRM2 in tumor tissue as well as in cervical cancer cell lines [43]. They 
were suggested as potential therapeutic targets, since their inhibition 
by interference RNA decreased proliferation of the tumor cells in 
vitro. Recently, the expression of PSEN1, a subunit of the gamma-
secretase complex, has been found increased in locally advanced 
cervical cancer compared to normal cervical tissue [44]. As for histone 
cluster 1 H3h, HIST1H3H, it is known to be overexpressed in cervical 
squamous cancer tissue compared to normal tissue (Human Protein 
Atlas available from www.proteinatlas.org). Moreover, a recent study 
combining transcriptomics, tissue microarray and molecular docking 
showed enhanced expression of this gene in renal cell carcinoma [45]. 
In conclusion there is a trend indicating that the methylation 
profile is similar in cervical swab samples from patients with CIN III 
and cervical cancer and clearly distinct of samples from with CIN I, 
CIN II patients and subjects with negative pathology. Further studies 
with larger numbers of patients should determine which of the genes 
identified here as differentially methylated have greater prognostic value.
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